Morgan Stanley Reiterates Equal-Weight on Pharvaris, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharvaris (NASDAQ:PHVS) and maintained a $10 price target.
June 12, 2023 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharvaris and maintained a $10 price target.
The news indicates that Morgan Stanley maintains its neutral stance on Pharvaris, with no change in the price target. This suggests that the analyst believes the stock is fairly valued and does not expect significant short-term price movement. As a result, the short-term impact on PHVS stock is neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100